Bioequivalence of a Hydroxyurea Oral Suspension (100 mg/mL) and Xromi® 100 mg/mL Oral Solution (100 mg Hydroxycarbamide) under Fasting Conditions: A Randomised, Open-label, Single-dose, Two-period Crossover Study
Abstract
Introduction: Hydroxyurea oral suspension is approved as an adjunctive treatment for Sickle Cell Disease (SCD) and Myeloproliferative Disorders (MPD). Oral liquid formulations ensure accurate dose administration, improve ease of use in patients with difficulty swallowing solid dosage forms, and may be administered with or without food. As patient-friendly formulations are increasingly needed, there is growing demand for a bioequivalent alternative to the marketed reference hydroxyurea oral solution. Aim: To evaluate the bioequivalence of hydroxyurea oral suspension (100 mg/mL) compared with the reference product, Xromi® (hydroxycarbamide oral solution 100 mg/mL), under fasting conditions. Materials and Methods: This open-label, two-treatment, twoperiod, two-sequence, single-dose crossover bioequivalence study was conducted under fasting conditions over six days at Vivotech Research Lab Pvt., Ltd., Navi Mumbai, Maharashtra, India. Healthy subjects were randomised to receive a single oral dose of 500 mg hydroxyurea as either the Test (Hydroxyurea Oral Suspension 100 mg/mL) or the Reference (Xromi®, Hydroxycarbamide Oral Solution 100 mg/mL), with a 3-day washout period. Plasma hydroxyurea concentrations were measured up to 24 hours using a validated Liquid chromatography-tandem mass spectrometry (LC-MS/ MS) method. Pharmacokinetic parameters (Cmax, AUC0-t, and AUC0-∞) were summarised using descriptive statistics and analysed by Analysis of Variance (ANOVA) on log-transformed data. Bioequivalence was assessed using geometric mean ratios (Test/Reference) and corresponding 90% confidence intervals (90% CIs). Results: Twenty-eight subjects completed both study periods and were included in the pharmacokinetic analysis. The geometric mean ratios (test/reference) and corresponding 90% CIs were 100.57% (93.49-108.18) for Cmax, 97.87% (93.82- 102.09) for AUC0-t, and 97.85% (93.84-102.02) for AUC0-∞. The 90% CIs for all three primary bioequivalence parameters were within the predefined bioequivalence acceptance range of 80.00-125.00%, demonstrating comparable rates and extents of absorption between the test and reference formulations. Both formulations were well tolerated, and all Adverse Events (AE) were mild and transient. Conclusion: Hydroxyurea oral suspension (100 mg/ mL) was bioequivalent to the reference product, Xromi® (Hydroxycarbamide Oral Solution 100 mg/mL), under fasting conditions. Both formulations were safe and well tolerated, supporting the oral suspension as an effective alternative for patients requiring a liquid oral dosage form.